Essential Partners’s DiaMedica Therapeutics DMAC Stock Holding History

Essential Partners’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2	Closed	-$14	–	2880
2026 Q1	$14	Buy	+2	New	+$16	﹤0.01%	2833

Other funds holding DMAC

CLG

Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Essential Partners's DMAC Position: Q2 2026 in Review

Essential Partners sold out of DiaMedica Therapeutics (DMAC) in Q2 2026, closing a stake of 2 shares — an estimated $14 sold.

Essential Partners first reported a position in DMAC in Q1 2026 and held it in 1 quarter. The position peaked at $14 in Q1 2026. 89 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

Essential Partners reported no remaining DiaMedica Therapeutics position as of Q2 2026 after selling out during the quarter.
Essential Partners sold 2 DiaMedica Therapeutics shares in Q2 2026, an estimated $14.
Essential Partners first reported a position in DiaMedica Therapeutics in Q1 2026 and held it in 1 quarter.
Essential Partners's DiaMedica Therapeutics position peaked at $14 in Q1 2026.
89 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.